Company intelligence / Profile preview

Genixcure

Suwon, Kyonggi-do, Korea, Republic ofgenix-cure.com ↗

Ownership: Private
Development stage: Other

Overview

Genixcure has developed proprietary AI-driven platforms to engineer next-generation AAV capsids with improved tropism and safety. Their pipeline includes several preclinical gene therapies targeting major neurodegenerative and rare genetic disorders. The company expects key updates from non-human primate studies by late 2025.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Gene therapyAAV-based gene therapymiRNA
Industry: Biotech

Partnerships

Local CRO partner for NHP studies in marmosets starting June/July 2025No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Genixcure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genixcure.

Explore the full profile